Table 1.
Demographic and diagnostic factors at study entry and GH treatment for patients from all participating HypoCCS countries.
| GH-treated (n=6840) | Non GH-treated (n=940) | |
|---|---|---|
| Sex | ||
| Male | 3571 (52%) | 549 (58%) |
| Female | 3269 (48%) | 391 (42%) |
| GH deficiency onseta | ||
| Adult (AO) | 5522 (81%) | 813 (86%) |
| Childhood (CO) | 1299 (19%) | 127 (14%) |
| Cause of GH deficiency | ||
| Pituitary adenoma | 45% | 54% |
| Craniopharyngioma | 11% | 9% |
| Other intracranial tumor | 7% | 9% |
| Idiopathic | 17% | 9% |
| Other diagnoses | 20% | 19% |
| No. of pituitary hormone deficiencies other than GH | ||
| 0 | 16% | 13% |
| 1 | 17% | 17% |
| 2 | 18% | 20% |
| 3 | 34% | 39% |
| 4 | 15% | 11% |
| Median age at study entry (years; Q1, Q3) | 46.4 (34.1, 56.3) | 54.4 (42.2, 65.6) |
| Median starting GH dose (mg/day; Q1, Q3) | 0.30 (0.20, 0.46) | NA |
| Mean±s.d. follow-up time in study (years) | 3.7±2.9 | 2.9±2.4 |
| Total patient-years in study | 25 034 | 2688 |
a
19 GH-treated patients, where onset of GHD was unknown.